110 related articles for article (PubMed ID: 17709622)
1. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Henderson YC; Fredrick MJ; Clayman GL
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
[TBL] [Abstract][Full Text] [Related]
2. Correlation Between the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated with Hashimoto's Thyroiditis, BRAF V600E Gene Mutation, and RET Gene Rearrangement.
Xie M; Xu ZX; Dai M; Zhu YY
J Coll Physicians Surg Pak; 2024 Apr; 34(4):445-450. PubMed ID: 38576288
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1.
Lanzi C; Cassinelli G; Cuccuru G; Zaffaroni N; Supino R; Vignati S; Zanchi C; Yamamoto M; Zunino F
Cell Mol Life Sci; 2003 Jul; 60(7):1449-59. PubMed ID: 12943231
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
Chen Y; Xiao X; Hu G; Liu R; Xue J
J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
[TBL] [Abstract][Full Text] [Related]
5. Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms.
Xu Q; Wang J; Mao Y; Xuan Z; Yang K; Tang X; Zhu X
Neoplasia; 2024 Jun; 52():100996. PubMed ID: 38593698
[TBL] [Abstract][Full Text] [Related]
6. Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway.
Weatherdon L; Stuart K; Cassidy M; de la Gándara AM; Okkenhaug H; Muellener M; Mckenzie G; Cook SJ; Gilley R
Biochem J; 2024 Mar; 481(6):405-422. PubMed ID: 38381045
[TBL] [Abstract][Full Text] [Related]
7. Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1.
Moretti S; Menicali E; Nucci N; Voce P; Colella R; Melillo RM; Liotti F; Morelli S; Fallarino F; Macchiarulo A; Santoro M; Avenia N; Puxeddu E
J Biol Chem; 2017 Feb; 292(5):1785-1797. PubMed ID: 27994058
[TBL] [Abstract][Full Text] [Related]
8. Targeting BRAF in thyroid cancer.
Espinosa AV; Porchia L; Ringel MD
Br J Cancer; 2007 Jan; 96(1):16-20. PubMed ID: 17179987
[TBL] [Abstract][Full Text] [Related]
9. BRAF and RET polymorphism association with thyroid cancer risk, a preliminary study from Khyber Pakhtunkhwa population.
Batool M; Khan NU; Khan H; Almutairi MH; Ali I; Adams BD
Mol Biol Rep; 2024 Apr; 51(1):502. PubMed ID: 38598020
[TBL] [Abstract][Full Text] [Related]
10. The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases.
Hu X; Liu X; Khatri U; Wu J
Drug Resist Updat; 2023 May; 68():100958. PubMed ID: 36990046
[TBL] [Abstract][Full Text] [Related]
11. Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targets in Thyroid Cancer.
Zhang W; Lin S; Wang Z; Zhang W; Xing M
J Clin Endocrinol Metab; 2024 May; ():. PubMed ID: 38735658
[TBL] [Abstract][Full Text] [Related]
12. Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA.
Della Corte CM; Morgillo F
ESMO Open; 2021 Feb; 6(1):100041. PubMed ID: 33477006
[No Abstract] [Full Text] [Related]
13. Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma.
Cavallo MR; Yo JC; Gallant KC; Cunanan CJ; Amirfallah A; Daniali M; Sanders AB; Aplin AE; Pribitkin EA; Hartsough EJ
Cell Death Discov; 2024 Apr; 10(1):175. PubMed ID: 38622136
[TBL] [Abstract][Full Text] [Related]
14. Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX; Li QQ; Cai J; Wu JZ; Wang JJ; Zhang MY; Wang QX; Tong ZJ; Yang J; Wei TH; Zhou Y; Dai WC; Ding N; Leng XJ; Sun SL; Xue X; Yu YC; Yang Y; Li NG; Shi ZH
J Med Chem; 2024 Mar; 67(6):4346-4375. PubMed ID: 38484122
[TBL] [Abstract][Full Text] [Related]
15. Advances in Targeting RET-Dependent Cancers.
Subbiah V; Cote GJ
Cancer Discov; 2020 Apr; 10(4):498-505. PubMed ID: 32094155
[No Abstract] [Full Text] [Related]
16. Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I; Odintsov I; Ishida K; Lui AJW; Kato M; Suzuki T; Zhang T; Wakayama K; Kurth RI; Cheng R; Fujita H; Delasos L; Vojnic M; Khodos I; Yamada Y; Ishizawa K; Mattar MS; Funabashi K; Chang Q; Ohkubo S; Yano W; Terada R; Giuliano C; Lu YC; Bonifacio A; Kunte S; Davare MA; Cheng EH; de Stanchina E; Lovati E; Iwasawa Y; Ladanyi M; Somwar R
Nat Cancer; 2023 Sep; 4(9):1345-1361. PubMed ID: 37743366
[TBL] [Abstract][Full Text] [Related]
17. Thyroid cancer cell lines: an overview.
Saiselet M; Floor S; Tarabichi M; Dom G; Hébrant A; van Staveren WC; Maenhaut C
Front Endocrinol (Lausanne); 2012; 3():133. PubMed ID: 23162534
[TBL] [Abstract][Full Text] [Related]
18. Sodium Selenite Enhanced the Anti-proliferative Effect of MEK-ERK Inhibitor in Thyroid Cancer Cells.
Kim JB; Yang EY; Woo J; Kwon H; Lim W; Moon BI
In Vivo; 2020; 34(1):185-190. PubMed ID: 31882478
[TBL] [Abstract][Full Text] [Related]
19. Src inhibitors in suppression of papillary thyroid carcinoma growth.
Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
Liu D; Xing J; Trink B; Xing M
Int J Cancer; 2010 Dec; 127(12):2965-73. PubMed ID: 21351275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
